Agilent Technologies Exceeds Q3 Street Expectations, Raises Guidance

Agilent Technologies Inc A reported third-quarter FY22 revenue growth of 8% year-over-year to $1.72 billion, +13% on a core basis, beating the consensus of $1.61 billion.

Revenues for the diagnostics and genomic group decreased 2% Y/Y to $340 million, and the operating margin for the quarter was 21.5%.

Revenues for the life sciences and applied markets group increased 14% to $1.02 billion, and revenues for the Agilent Crosslab Group grew 5% to $359 million.

Adjusted net income was $401 million, or $1.34 per share, up 22% Y/Y, beating the consensus of $1.18.

The operating income increased 22.3% Y/Y to $411 million, and the margin expanded by 275 bps to 23.9%.

Agilent’s net cash provided by operating activities year-to-date was $864 million, compared to $1.04 billion a year ago. It held cash and cash equivalents of $1.07 billion as of July 31, 2022.

4Q22 Outlook: Agilent expects revenues of $1.75 billion - $1.775 billion vs. consensus of $1.71 billion; and adjusted EPS of $1.38 - $1.40, vs. consensus of $1.29.

FY22 Outlook: The company raised revenue guidance to $6.750 billion to $6.775 billion (prior $6.67 billion to $6.73 billion) vs. a consensus of $6.51 billion; and adjusted EPS to $5.06 to $5.08 per share (previous $4.86 to $4.93 per), vs. consensus of $4.76.

Price Action: A shares are trading higher by 5.54% at $140.09 during the post-market session on Tuesday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsGuidanceAfter-Hours CenterMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!